Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 hospitalized meta-analysis

ACTT-2 (Kalil), 2020
 
NCT04401579
RCTbaricitinib plus remdesivirremdesivirCOVID 19 hospitalizedlow
515/518 conclusif
  • demonstrated 16 % increase in clinical improvement,time to recovery (PE) with a high degree of certainty due to low risk of bias
  • suggested 31 % decrease in death or ventilation with a high degree of certainty due to low risk of bias

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).